

September 1st, 2009

Archimica Group and Chemic Laboratories Inc Announce Joint Cooperation Agreement

Chemic Laboratories Inc. and Archimica Group today announced a joint cooperation agreement that will enable the two pharmaceutical development and manufacturing firms to cooperate on a variety of client engagements, primarily in the areas of Active Pharmaceutical Ingredient (API) research, development and production. Under this agreement, the companies can now leverage their collective expertise in pharmaceutical analytics, development and commercial manufacturing to make a definitive difference in their client's business performance speeding the time products can be brought to market.

"Chemic is very pleased to establish this formal working relationship with Archimica Group, which has a strong reputation as a global leader in the area of pharmaceutical API commercialization", said Joseph St. Laurent, President and CSO of Chemic Laboratories Inc. This joint agreement places our two firms at the forefront of the rapidly expanding marketplace of companies that are seeking to further outsource their pharmaceutical API development and commercial manufacturing activities.

Andreas Meudt, Managing Director of New Business Development for Archimica Group, commented that "The cooperation with Chemic Laboratories is another step in the strategy of Archimica to support its customers with rapid commercialization services in the areas of innovative API, DEA controlled drugs and high-tech building blocks". Via this cooperation, Archimica is further pursuing its focus on high-value products with significant differentiation on the technological and on the regulatory side and further expands the Archimica offering for DEA regulated materials.

The cooperation model between the two companies will consist in Archimica quickly scaling DEA controlled and other API to commercial scale after Chemic Laboratories have developed and produced the first quantities, resulting in very fast and reliable supply of customers with highest quality API. Together with the existing DEA controlled drug portfolio and several new controlled APIs under development, this is another step forward in broadening the company portfolio.

Contact:

Dr. Andreas Meudt

Archimica
Industriepark Höchst
65926 Frankfurt am Main

andreas.meudt@archimica.com

Media Release

www.archimica.com

About Chemic Laboratories, Inc.:

Your Partner for a Successful Future©

Chemic Laboratories is a privately held full service FDA registered and DEA licensed, cGMP/ GLP Contract Chemistry Organization (CCO) founded in 1998. Chemic offers unparalleled contract Analytical, API Synthesis, and Formulation Development, to the Pharmaceutical, Biotech, and Medical Device industries. Chemic Laboratories offers these services by providing a strategically designed, highly technical facility, equipped with state of the art instrumentation. All programs can be conducted under the strict auspices of FDA and EMEA guidelines.

For more information contact:

Chemic Laboratories, Inc.
Client Services
480 Neponset Street, Bldg 7
Canton, MA 02021



Phone: +1-781-821-5600
Web: www.chemiclabs.com
Email: SSB@Chemiclabs.com

Archimica – Strong. Steady. Focused on Pharmaceuticals.

Archimica is a privately held leading pharmaceutical fine chemicals company that combines world-scale chemical manufacturing experience with a history of pharmaceutical commercialization that stretches back over 40 years. Archimica is particularly focused on the custom synthesis of innovative building blocks, intermediates and APIs in close cooperation with its clients. The company has more than 600 employees at seven production sites in Italy, France, Germany, US and UK and sales of € 112 million in 2008. Archimica's core technologies are cryogenic reactions especially for boronic acids, Pd-catalyzed chemistries for biaryls and C,X-couplings, hydrogenations up to 80 bar, phosgenation with triphosgene, heterocyclic products, enzymatic chemistries, nitrations and aseptic filtration for bulk steriles.

Contact:

Dr. Andreas Meudt

Archimica
Industriepark Höchst
65926 Frankfurt am Main

andreas.meudt@archimica.com